Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]-

Request For Quotation
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Suppliers list
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696，15000506266 15000506266
Email:
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ：65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Shanghai Dongyang Biotechnology Co., Ltd.  
Tel: 0512-13601744364 13601744364
Email: chemsharker@126.com

Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- manufacturers

  • Dalpiciclib
  • Dalpiciclib pictures
  • $152.00
  • 2026-07-27
  • CAS:1637781-04-4
  • Purity: 99.69%
  • Supply Ability: 10g
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Basic information
Product Name:Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]-
Synonyms:Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]-;Dalpiciclib (Synonyms: SHR-6390);SHR-6390;Dalpiciclib free base;MCF7,BT-474/T,Cyclin dependent kinase,Eca 109,MCF7/TR,and KYSE-510 ESCC,SHR6390,Inhibitor,Dalpiciclib,inhibit,Eca 9706,SHR 6390,antitumor activity,CDK;Dalpiciclib/SHR-6390;6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperidin-4-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one;6-Acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
CAS:1637781-04-4
MF:C25H30N6O2
MW:446.54
EINECS:
Product Categories:
Mol File:1637781-04-4.mol
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Structure
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Chemical Properties
Boiling point 674.3±65.0 °C(Predicted)
density 1.277±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
pka9.96±0.10(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Usage And Synthesis
UsesDalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC50 values of 12.4 nM and 9.9 nM, respectively[1][2]. Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma[1][2][3][4].
in vivo

Dalpiciclib (oral gavage; 150 mg/kg; once weekly; 3 weeks) shows antitumor activity against ESCC xenografts[3].
Dalpiciclib combined with Paclitaxel (PTX) or Cisplatin (CDDP) offer synergistic inhibitory effects in ESCC xenografts[3].
Dalpiciclib (oral gavage; 37.5 mg/kg, 75 mg/kg, 150 mg/kg; once daily; 30 days) shows antitumor activity in human xenograft models [4].

Animal Model:NOD/SCID mice (ESCC PDXs models) [3]
Dosage:150 mg/kg
Administration:Oral gavage; 150 mg/kg; once weekly; 3 weeks
Result:Suppressed the growth of tumor.
Animal Model:5-week-old female Balb/cA-nude mice subcutaneously inoculated MCF7/ARO, COLO 205 and U87MG[4]
Dosage:37.5 mg/kg, 75 mg/kg, 150 mg/kg
Administration:Oral gavage; 37.5 mg/kg, 75 mg/kg, 150 mg/kg; once daily; 30 days
Result:Caused regression of all tumor xenografts at the highest dose tested.
IC 50CDK4: 12.4 nM (IC50); CDK6: 9.9 nM (IC50)
References[1] Jose Manuel Perez-Garcia, et al. Perez-Garcia JM, Cortes J, Llombart-Cussac A. CDK4/6 inhibitors in breast cancer: spotting the difference. Nat Med. 2021 Nov;27(11):1868-1869. DOI:10.1038/s41591-021-01570-9
[2] Pin Zhang, et al. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021 Apr 12;9(1):24. DOI:10.1186/s40364-021-00271-2
[3] Jiayuan Wang, et al. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. 2017 Jun 2;15(1):127. DOI:10.1186/s12967-017-1231-7
[4] Fei Long, et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci. 2019 Apr;110(4):1420-1430. DOI:10.1111/cas.13957
Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]- Preparation Products And Raw materials
Tag:Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(4-piperidinyl)-2-pyridinyl]amino]-(1637781-04-4) Related Product Information
CDK12-CCNK HETERODIMER Protein, HUMAN (SF9) CDK3-CCNE1 HETERODIMER Protein, HUMAN (SF9) OTS964 hydrochloride GSK-3326595 DRB CDK2 Protein, HUMAN (HIS)